AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM …
Over the last 12 months, insiders at AxoGen, Inc. have bought $0 and sold $1.07M worth of AxoGen, Inc. stock.
On average, over the past 5 years, insiders at AxoGen, Inc. have bought $188,940 and sold $2.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $62,240 was made by Wendell Amy McBride (director) on 2023‑09‑06.
2024-03-21 | Sale | CEO | 39,280 0.091% | $7.68 | $301,670 | +5.15% | ||
2024-03-21 | Sale | Chief Innovation Officer | 4,578 0.0106% | $7.68 | $35,159 | +5.15% | ||
2024-03-21 | Sale | Chief R&D Officer | 6,881 0.0159% | $7.68 | $52,846 | +5.15% | ||
2024-03-21 | Sale | VP Operations | 6,033 0.014% | $7.68 | $46,333 | +5.15% | ||
2024-03-07 | Sale | director | 25,000 0.0581% | $9.00 | $225,000 | -10.70% | ||
2024-03-07 | Sale | VP Operations | 36,310 0.0826% | $8.81 | $319,891 | -10.70% | ||
2023-12-11 | Sale | EVP & Chief Financial Officer | 12,500 0.0291% | $7.50 | $93,809 | +12.33% | ||
2023-09-06 | director | 10,000 0.0235% | $6.22 | $62,240 | +16.26% | |||
2023-08-23 | director | 10,000 0.0234% | $6.56 | $65,600 | +7.44% | |||
2023-08-16 | director | 10,000 0.0252% | $6.11 | $61,100 | +23.36% | |||
2023-06-01 | Sale | director | 41,980 0.0994% | $8.71 | $365,780 | -18.63% | ||
2023-05-23 | Sale | director | 7,468 0.0176% | $9.23 | $68,899 | -21.55% | ||
2023-02-01 | Sale | EVP & Chief Financial Officer | 14,550 0.0348% | $9.36 | $136,188 | -11.25% | ||
2023-01-31 | Sale | EVP & Chief Financial Officer | 14,320 0.0343% | $9.55 | $136,756 | -12.94% | ||
2023-01-30 | Sale | EVP & Chief Financial Officer | 14,111 0.0334% | $9.69 | $136,736 | -15.26% | ||
2023-01-27 | Sale | EVP & Chief Financial Officer | 20,940 0.0495% | $10.16 | $212,750 | -19.29% | ||
2022-11-16 | Sale | EVP & Chief Financial Officer | 10,649 0.027% | $11.88 | $126,510 | -24.25% | ||
2022-11-14 | Sale | director | 13,000 0.0339% | $12.74 | $165,620 | -27.03% | ||
2022-11-08 | Sale | director | 13,000 0.0337% | $12.50 | $162,500 | -25.66% | ||
2022-08-10 | Sale | 8,886 0.0204% | $9.70 | $86,159 | -4.15% |
Zaderej Karen L. | CEO | 1124565 2.5553% | $13.13 | 9 | 8 | +15.63% |
Freitag Gregory Gene | director | 271594 0.6171% | $13.13 | 6 | 12 | +24.07% |
MARIANI PETER J | EVP & Chief Financial Officer | 63603 0.1445% | $13.13 | 1 | 9 | +19.13% |
Mandato Joseph M | director | 1226773 2.7876% | $13.13 | 1 | 4 | +61.29% |
Hopfenspirger Larry | 10 percent owner | 426066 0.9681% | $13.13 | 1 | 0 |
Arrowmark Colorado Holdings Llc | $38.14M | 10.82 | 4.73M | -8.26% | -$3.43M | 0.1 | |
BlackRock | $26.08M | 7.4 | 3.23M | -3.31% | -$892,267.67 | <0.01 | |
Morgan Stanley | $25.67M | 7.28 | 3.18M | +3.18% | +$791,997.89 | <0.01 | |
Soleus Capital Management, L.P. | $25.06M | 7.11 | 3.11M | +19.65% | +$4.12M | 0.1 | |
The Vanguard Group | $19.46M | 5.52 | 2.41M | -2.19% | -$436,530.51 | <0.0001 |